• DEA Schedule: CIV
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated October 4, 2012

If you are a consumer or patient please visit this version.

  • Phentermine Hydrochloride Capsules, USP

    Rx Only     



    Phentermine hydrochloride has the chemical name of α, α, -Dimethylphenethylamine hydrochloride. The structural formula is as follows:


    Phentermine hydrochloride, is a white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols; slightly soluble in chloroform and insoluble in ether.

    Phentermine hydrochloride, an anorectic agent for oral administration, is available as:

    a) powder-filled capsules containing 15 mg Phentermine hydrochloride (equivalent to 12 mg Phentermine) or 30 mg Phentermine hydrochloride (equivalent to 24 mg Phentermine) and inactive ingredients: corn starch, gelatin, lactose monohydrate and magnesium stearate. In addition, the 15 mg capsules contain D&C Yellow #10, FD&C Blue #1, FD&C Red #3, FD&C Red #40, titanium dioxide and the 30 mg capsules contain D&C Yellow #10, FD&C Red #3, titanium dioxide.

    b) bead-filled capsules containing 30 mg Phentermine hydrochloride (equivalent to 24 mg Phentermine) and inactive ingredients: corn starch, sucrose, hypromellose, povidone, and talc. In addition, the capsule contains FD&C blue #1/Brilliant blue FCF aluminum lake, D&C red #28 and gelatin.


    Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

    Drugs of this class used in obesity are commonly known as “anorectics” or “anorexigenics.” It has not been established that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions, or metabolic effects, may be involved, for example. Adult obese subjects instructed in dietary management and treated with “anorectic” drugs lose more weight on the average than those treated with placebo and diet, as determined in relatively short-term clinical trials. The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an “anorectic” drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator, the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.

    The natural history of obesity is measured in years, whereas the studies cited are restricted to a few weeks’ duration; thus, the total impact of drug induced weight loss over that of diet alone must be considered clinically limited.


    Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30 kg/m2, or ≥27 kg/m2 in the presence of other risk factors (e.g., hypertension, diabetes, hyperlipidemia).

    Below is a chart of Body Mass Index (BMI) based on various heights and weights.

    BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.


    The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below.


    Advanced arteriosclerosis, cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma.

    Agitated states.

    Patients with history of drug abuse.

    During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).


    Phentermine hydrochloride capsules are indicated only as short-term monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss, including selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of these drug products for weight loss is not recommended.

    Primary Pulmonary Hypertension (PPH) – a rare, frequently fatal disease of the lungs – has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom of PPH is usually dyspnea. Other initial symptoms include: angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema.

    Valvular Heart Disease: Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between valvular heart disease and

    the use of phentermine alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone.

    Tolerance to the anorectic effect usually develops within a few weeks. When this occurs, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued. Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.

    Usage with Alcohol: Concomitant use of alcohol with phentermine may result in an adverse drug interaction.



    Caution is to be exercised in prescribing phentermine hydrochloride for patients with even mild hypertension. Insulin requirements in diabetes mellitus may be altered in association with the use of phentermine and the concomitant dietary regimen.

    Phentermine may decrease the hypotensive effect of guanethidine. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.

    Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies have not been performed with phentermine hydrochloride to determine the potential for carcinogenesis, mutagenesis or impairment of fertility.

    Pregnancy-Teratogenic Effects: Pregnancy Category C. Animal reproduction studies have not been conducted with phentermine hydrochloride. It is also not known whether phentermine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Phentermine should be given to a pregnant woman only if clearly needed.

    Nursing Mothers

    Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

    Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.


    Cardiovascular: Primary pulmonary hypertension and/or regurgitant cardiac valvular disease (see WARNINGS), palpitation, tachycardia, elevation of blood pressure.

    Central Nervous System: Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache; rarely psychotic episodes at recommended doses.

    Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.

    Allergic: Urticaria.

    Endocrine: Impotence, changes in libido.


    Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and related stimulant drugs have been extensively abused, and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia.


    Manifestations of acute overdosage with phentermine include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Fatal poisoning usually terminates in convulsions and coma.

    Management of acute phentermine intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine has been suggested for possible acute, severe hypertension, if this complicates phentermine overdosage.


    Dosage should be individualized to obtain an adequate response with the lowest effective dose.

    Exogenous Obesity: The usual adult dose is 15 mg to 30 mg at approximately 2 hours after breakfast for appetite control. Late evening medication should be avoided because of the possibility of resulting insomnia. Administration of one capsule (30 mg) daily has been found to be adequate in depression of the appetite for 12 to 14 hours.

    Phentermine is not recommended for use in patients 16 years of age and under.


    Phentermine hydrochloride capsules, USP are available as follows:

    Phentermine hydrochloride capsules, USP 15 mg are supplied as gray opaque cap, rich yellow opaque body with black imprint “K 26” on both the cap and body, filled with powder.

    Bottles of 7,         NDC 33261-361-07
    Bottles of 8,         NDC 33261-361-08
    Bottles of 14,       NDC 33261-361-14
    Bottles of 15,       NDC 33261-361-15
    Bottles of 23,       NDC 33261-361-23
    Bottles of 28,       NDC 33261-361-28
    Bottles of 30,       NDC 33261-361-30
    Bottles of 40,       NDC 33261-361-40
    Bottles of 45,       NDC 33261-361-45
    Bottles of 60,       NDC 33261-361-60

    Phentermine hydrochloride capsules, USP 30 mg are supplied as blue cap, natural body with black imprint “K 28” on both the cap and body, filled with white and blue colored beads.

    Bottles of 7,       NDC 33261-366-07
    Bottles of 8,       NDC 33261-366-08
    Bottles of 14,     NDC 33261-366-14
    Bottles of 15,     NDC 33261-366-15
    Bottles of 23,     NDC 33261-366-23
    Bottles of 28,     NDC 33261-366-28
    Bottles of 30,     NDC 33261-366-30
    Bottles of 40,     NDC 33261-366-40
    Bottles of 45,     NDC 33261-366-45
    Bottles of 60,     NDC 33261-366-60

    Store at 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from moisture.

    Dispense in a tight, light resistant container as defined in the USP, with a child-resistant closure (as required). Protect from moisture.

    Manufactured by:


    110 Terry Drive

    Newtown, PA 18940.


    Item ID # 006070/00

    Manufacturer’s Code: 10702     03/08

    Repackaged By:
    Aidarex Pharmaceuticals, LLC
    Corona, CA 92280


    Image Label

    Image Label
    phentermine hydrochloride capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:33261-361(NDC:10702-026)
    Route of AdministrationORALDEA ScheduleCIV    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Inactive Ingredients
    Ingredient NameStrength
    GELATIN (UNII: 2G86QN327L)  
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    Product Characteristics
    ColorYELLOW, GRAYScoreno score
    FlavorImprint Code K;26
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:33261-361-077 in 1 BOTTLE
    2NDC:33261-361-088 in 1 BOTTLE
    3NDC:33261-361-1414 in 1 BOTTLE
    4NDC:33261-361-1515 in 1 BOTTLE
    5NDC:33261-361-2323 in 1 BOTTLE
    6NDC:33261-361-2828 in 1 BOTTLE
    7NDC:33261-361-3030 in 1 BOTTLE
    8NDC:33261-361-4040 in 1 BOTTLE
    9NDC:33261-361-4545 in 1 BOTTLE
    10NDC:33261-361-6060 in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    phentermine hydrochloride capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:33261-366(NDC:10702-028)
    Route of AdministrationORALDEA ScheduleCIV    
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Inactive Ingredients
    Ingredient NameStrength
    SUCROSE (UNII: C151H8M554)  
    TALC (UNII: 7SEV7J4R1U)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    D&C RED NO. 28 (UNII: 767IP0Y5NH)  
    GELATIN (UNII: 2G86QN327L)  
    Product Characteristics
    ColorBLUEScoreno score
    FlavorImprint Code K;28
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:33261-366-077 in 1 BOTTLE
    2NDC:33261-366-088 in 1 BOTTLE
    3NDC:33261-366-1414 in 1 BOTTLE
    4NDC:33261-366-1515 in 1 BOTTLE
    5NDC:33261-366-2323 in 1 BOTTLE
    6NDC:33261-366-2828 in 1 BOTTLE
    7NDC:33261-366-3030 in 1 BOTTLE
    8NDC:33261-366-4040 in 1 BOTTLE
    9NDC:33261-366-4545 in 1 BOTTLE
    10NDC:33261-366-6060 in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Labeler - Aidarex Pharmaceuticals LLC (801503249)